Natixis Advisors LLC Boosts Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Natixis Advisors LLC raised its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 12.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,840 shares of the biotechnology company's stock after purchasing an additional 3,229 shares during the quarter. Natixis Advisors LLC's holdings in Axon Enterprise were worth $8,486,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. GraniteShares Advisors LLC grew its stake in Axon Enterprise by 22.4% in the second quarter. GraniteShares Advisors LLC now owns 2,325 shares of the biotechnology company's stock valued at $684,000 after acquiring an additional 426 shares during the period. D.A. Davidson & CO. grew its stake in Axon Enterprise by 2.2% in the second quarter. D.A. Davidson & CO. now owns 12,578 shares of the biotechnology company's stock valued at $3,701,000 after acquiring an additional 273 shares during the period. Interchange Capital Partners LLC acquired a new stake in Axon Enterprise in the second quarter valued at approximately $366,000. Ascent Wealth Partners LLC grew its stake in Axon Enterprise by 1.8% in the second quarter. Ascent Wealth Partners LLC now owns 20,951 shares of the biotechnology company's stock valued at $6,165,000 after acquiring an additional 368 shares during the period. Finally, Banque Cantonale Vaudoise acquired a new stake in Axon Enterprise in the second quarter valued at approximately $2,123,000. 79.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Axon Enterprise

In related news, Director Matthew R. Mcbrady sold 2,000 shares of the business's stock in a transaction on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the sale, the director now directly owns 4,892 shares in the company, valued at approximately $1,783,916.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business's stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the transaction, the director now directly owns 7,379 shares in the company, valued at $2,752,588.37. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Matthew R. Mcbrady sold 2,000 shares of the business's stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the transaction, the director now owns 4,892 shares of the company's stock, valued at $1,783,916.72. The disclosure for this sale can be found here. Insiders have sold a total of 278,650 shares of company stock worth $101,364,745 over the last ninety days. 6.10% of the stock is currently owned by company insiders.

Axon Enterprise Stock Performance

Shares of AXON traded down $0.24 during mid-day trading on Friday, hitting $354.62. The stock had a trading volume of 509,150 shares, compared to its average volume of 514,277. The firm has a market cap of $26.80 billion, a P/E ratio of 103.69, a PEG ratio of 9.52 and a beta of 0.94. The business has a fifty day moving average price of $331.40 and a 200-day moving average price of $311.15. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. Axon Enterprise, Inc. has a 52 week low of $189.12 and a 52 week high of $378.89.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business's revenue was up 34.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.80 earnings per share. On average, equities research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AXON shares. Barclays raised their price objective on Axon Enterprise from $381.00 to $387.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. Robert W. Baird lifted their target price on Axon Enterprise from $355.00 to $360.00 and gave the company an "outperform" rating in a research report on Wednesday, August 7th. Northland Securities lifted their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an "outperform" rating in a research report on Thursday, August 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $400.00 target price on shares of Axon Enterprise in a research report on Wednesday, August 7th. Finally, Bank of America initiated coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a "buy" rating and a $380.00 target price on the stock. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $358.08.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.